ログイン
ランキング
お知らせ
ログイン
文献詳細
総説
文献概要
新規抗てんかん薬の単剤使用が認められ，成人てんかん患者の治療戦略は大きく変化している。新規薬は薬効の点で従来薬に勝るわけではないが，副作用が少なく，薬物相互作用がない点で優れている。従来薬の長期投与に伴い問題となる骨代謝・脂質代謝への影響がないのも利点である。特に高齢者や妊娠可能女性への使用が強く推奨される。てんかん治療の最終目標である「副作用のない発作消失」を維持するために欠かせない選択肢である。
参考文献
1) Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30: 389-390, 1989
2) 「てんかん治療ガイドライン」作成委員会: てんかん治療ガイドライン2010．医学書院, 東京, 2010
3) Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, et al: Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009．Epilepsia 51: 676-685, 2010
4) Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 34: 314-319, 2000
5) Nicholas JM, Ridsdale L, Richardson MP, et al. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: Cohort study using the General Practice Research Database. Seizure 21: 466-470, 2012
6) Karceski S, Morrell MJ, Carpenter Dm. Treatment of epilepsy in adults: expertopinion, 2005．Epilepsy Behav 7(Suppl 1): S1-S64, 2005
7) National Institute for Health and Clinical Excellence (NICE) guidelines: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Appendix E: pharmacological treatment. 2012 http://www.nice.org.uk/cg137
8) Brodie MJ, Sills GJ: Combining antiepileptic drugs-rational polytherapy? Seizure 20: 369-375, 2011
9) Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, et al: Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41: 1364-1374, 2000
10) Panayiotopoulos CP: Pharmacopoeia. Panayiotopoulos CP (ed): A Clinical Guide to Epileptic Syndromes and their Treatment. Revised 2nd ed. Springer, London, 2010, pp565-620
11) 兼本浩祐: 第6章 抗てんかん薬. 兼本浩祐（編著): てんかん学ハンドブック 第3版. 医学書院, 東京, 2012,pp257-287
12) Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, et al: Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52: 1280-1291, 2011
13) Jette N, Hemming K, Hutton JL, Marson AG: Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3: CD001417, 2008
14) Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, et al; Topiramate TPS-TR Study Group: Topiramate titration and tolerability. Ann Pharmacother 35: 173-179, 2001
15) Mula M, Hesdorffer DC, Trimble M, Sander JW: The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 50: 1072-1076, 2009
16) 兼子 直, 井上有史, 鮫島正文, 石田篤子, 井尻章悟, 他: てんかん患者を対象としたラモトリギン錠の使用成績調査——中間解析結果. 新薬と治療60: 9-35, 2011
17) Ramaratnam S, Marson AG, Baker GA: Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 3: CD001909, 2001
18) Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, et al: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198, 2006
19) Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, et al; EURAP study group: Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-17, 2011
20) 八木和一: Levetiracetam——新規抗てんかん薬の期待. 臨床精神薬理13: 1660-1670, 2010
21) Chaisewikul R, Privitera MD, Hutton JL, Marson AG: Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev 1: CD001901, 2001
22) Ramsay RE, Pryor F: Epilepsy in the elderly. Neurology 55(Suppl 1): S9-S14, 2000
23) Mohanraj R, Brodie MJ: Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13: 277-282, 2006
24) Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, et al: New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64: 1868-1873, 2005
25) Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, et al: Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 67: 408-415, 2010
26) Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, et al: A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 56: 450-459, 2015
27) Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, et al: Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617, 2011
28) Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, et al: Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry 85: 1029-1034, 2014
29) Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, et al: IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology 84: 382-390, 2015
30) Tomson T, Marson A, Boon P, Canevini MP, Covanis A, et al: Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia 56: 1006-1019, 2015
31) Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, et al: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369: 1016-1026, 2007
掲載誌情報
